Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks man! At least someone in this big ole world appreciates what I do...lol! Once we CLOSE above that 250 EMA it will be game on... Make sure you are wearing a seat-belt....
AVCO on launch pad - chart analysis
Yesterday was a significant day for AVCO.
A huge sideways coiling price action has occurred over the last 4 months. This type of action is often a precursor to a big move.
The OBV (On Balance Volume indicator) broke out yesterday to the upside from the nearly 4 month sideways coiling price action. Will price soon follow? Not always but it often does....
The 10 EMA just crossed up and above the 50 EMA...(not noted on the chart).
Yesterday's low tested the recent breakout area around the 50 day EMA.
We have had above average volume over the last 3 days. These included two huge separate buy orders you can see if you look at a 5 min chart. Someone with a lot of money is accumulating this stock below $2.00.
Many many positive fundamentals in the works along with excellent management and share structure.
We just need to make a solid close up above the critical $1.80 area noted on the chart. If this occurs we should see a very large upward move develop. First target would be the $2.50 area. Then $5.00 to fill in the huge gap left back on April 25th 2019. Then the target of $13.00, the all time high, and then who knows from there but potentially much higher.
Things could get interesting here soon for AVCO!
This is my opinion...do your own due diligence!
Excellent stuff hayfarmer...thank you!
Buy PROF on the retracements (like what it's doing right now) and don't let go...long term investment IMHO!!
Yes...very good news to build off of...
Notice where the low of the day is...
Post #208 "Would not be surprised if AVCO briefly dips/spikes back down and tests the 1.68 - 1.65 breakout area before we really get going to the upside here."
So we got the test...check...now let's see now if we can start to move up and break thru your 250 EMA!!
I should have included the title with the Summary:
Also going to include the 1st paragraph and hope I don't piss off anyone over at SA. If so an admin can pull this. I like SA btw..! Lot of good info there...
Profound Medical: Momentum Continues To Build
Aug. 12, 2020 9:34 AM ET|1 comment | About: Profound Medical Corp. (PROF)
TJ Roberts
Summary
Profound should obtain its CMS insurance billing code within 3 weeks.
Florida Mayo Clinic adopts TULSA-PRO.
New revenue strategy of renting versus capital sales.
Pandemic spotlights clinic advantage over hospitals.
Company financial health with no debt and $112 million in cash.
The latest Profound Medical (PROF) Q2-2020 earnings call offered quite a few gold nuggets to investors, specifically - 1) the company's obtaining of an insurance billing code in a few weeks, 2) the addition of yet another TULSA-PRO site with more on the horizon, 3) a new revenue strategy for TULSA-PRO offering a much wider customer audience and 4) the announcement of the company's financial health with no debt and $112 million in cash liquidity. The recent offering at $14.50 per share netted ~$46 million for the company coffers and was a shrewd move that further ensures a successful roll-out of their vanguard TULSA-PRO product which is the gentlest, most superior and flexible prostate treatment on the market. In my opinion, at current share pricing of ~$14.50, PROF is a gold nugget for the taking, an Enphase Energy (ENPH) or Apple (AAPL) of the prostate arena.
-----
And it goes on from there but that's all I dare copy....
Positive article out today about PROF on Seeking Alpha
TJ Roberts has written another updated analysis on PROF for SA members...I think it will be alright to copy/paste the summary here:
Summary:
Profound should obtain its CMS insurance billing code within 3 weeks.
Florida Mayo Clinic adopts TULSA-PRO.
New revenue strategy of renting versus capital sales.
Pandemic spotlights clinic advantage over hospitals.
Company financial health with no debt and $112 million in cash.
Avalon GloboCare Expands AVA-Trap™ Program to Treat COVID-19 and CAR-T Related Cytokine Storms
Wed August 12, 2020 9:00 AM|GlobeNewswire|About: AVCO
Wed August 12, 2020 9:00 AM|GlobeNewswire|About: AVCO
Expands and files two USPTO provisional patent applications jointly with the Massachusetts Institute of Technology (MIT) Media Lab to develop a cytokine-specific blood purification system based on Avalon’s proprietary AVA-Trap™ technology
Reflects advancements to Avalon’s AVA-Trap™ blood filtration system designed to rid the body of cytokines unleashed during the “cytokine storm” and acute respiratory distress syndrome (ARDS) in COVID-19 patients, as well as cancer patients treated with CAR T-cell therapy and other patients that require rapid removal of cytokines from the body
The expanded patent application combines two novel technologies—S-layers and a protein design code tool—for a decoy cytokine receptor system to filter out pro-inflammatory cytokine levels in the blood in those experiencing cytokine storm
FREEHOLD, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that Avalon has expanded and filed two provisional patents with the U.S. Patent and Trademark Office outlining compositions and methods of developing a decoy cytokine receptor-based filter system to treat “cytokine storms.” These provisional patent applications are direct results of recent advancements related to Avalon’s AVA-Trap™ therapeutic program. The technology utilizes cytokine receptor–Fc-fusion proteins to potentially serve as an antibody-like decoy to dampen the excessive cytokine release that occurs during hyper-activation of the immune system—a life-threatening condition called “cytokine storm” that can cause multi-organ failure and death.
Patients infected with the SARS-CoV-2 virus that causes COVID-19 are susceptible to developing cytokine storms, which occur when the immune system suddenly produces high levels of inflammatory proteins called cytokines that concentrate in the blood. The extracorporeal hemo-purifier device is designed to provide potential treatment for patients experiencing cytokine storms induced by COVID-19, hepatitis, HIV, influenza, graft-versus-host disease, and cytokine release syndrome associated with CAR-T cell therapy.
The expanded patent application was jointly filed with Professor Shuguang Zhang of the Massachusetts Institute of Technology (MIT) Media Lab, and Professor Uwe Sleytr, a full member of the Austrian Academy of Sciences and pioneer of applied surface layer (“S-layer”) nanotechnology.
The application combines Avalon’s AVA-Trap™ program with two innovative technologies. The first is the QTY code protein design platform, which was developed together with Professor Shuguang Zhang’s laboratory at MIT. This technology platform can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be used in many clinical applications. The second technology is applied S-layer nanotechnology, based on the repetitive protein structures that make up the outer surface of microbial cells. Coating of S-layers on solid surfaces can greatly enhance the binding orientation and efficiency of targeted ligand proteins that are directed to bind to, and capture, molecules of choice in the blood.
Together, Avalon is developing these unique technologies to advance an extracorporeal hemodialysis and hemo-purification device consisting of membrane protein receptors for specific cytokines coated onto an S-layer-based matrix that can be used to specifically filter out cytokines responsible for a “cytokine storms” in patients experiencing this immune system attack on the body, including patients with COVID-19.
While non-specific blood filtration systems exist, the clinical AVA-Trap™ blood filtration system would specifically target cytokine storm-causing proteins, allowing the detection and recovery of cytokines—and serving as a potential clinical therapy as well as a diagnostic tool. Importantly, it is the Company’s goal to develop a filtration system that can be customized to trap only specific molecules.
“We are grateful for our strong scientific partnerships that enabled the rapid speed with which we are developing this novel clinical tool,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “This medical device holds enormous promise as it directly addresses a leading cause of mortality for patients with illnesses that make them vulnerable to the damaging effects of a cytokine storm,” added Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
You are welcome! Thanks for the 250 EMA tip. Have always kept track of the 200 EMA but doing a quick glance looks like the 250 may be better.
Amazing how few people are on this board. That will change when this starts to take off but then it will be too late to get the real cheapies under $2.00...
Yep...I like it...if it does break down a bit more...probably will be testing the $14 area. I am however a very long term investor on this and am heavily loaded. As long as you know that the fundamentals/management/price structure are rock solid, like they are are for PROF and don't jump off the roller coaster you should be all right buying right around here IMHO. But that's just me ...you do you.
Excellent observation of the 250 EMA. Like it!
We did jump up above the all important 50 EMA and is currently at 1.67 and is another reason why I mentioned we may end up testing that area.
Will be keeping a close eye on that 250 EMA. We close above that this time around, good chance we never look back...
Yes...could not agree more with the good doctor of the IBIO group...he was a bit early on his recommendation for this stock but that's okay (I was too). Buy as much AVCO under $2.00 while you can and it will dramatically change your financial life for the better over the next 12-24 months IMHO.
The sideways coiling back and fill price action of AVCO over the last 4 months is creating a solid platform for AVCO to launch from. Most novice investors will see this as a sign of weakness...get bored, sell and move on. As long as you know the fundamentals/management/share structure are rock solid (they are exceptional for AVCO) then you have an excellent chance of making a lot of money if you have the patience to wait.
Look at any daily/weekly stock chart and you will see lots of big moves preceded by sideways back and fill periods. This principal is also true for the commodity and currency markets. Day leads to night, quiet periods lead to volatile periods etc etc and around and around we go.
Would not be surprised if AVCO briefly dips/spikes back down and tests the 1.68 - 1.65 breakout area before we really get going to the upside here.
Expect any kind of news to launch us...buyout rumors, Covid 19 vaccine news...who knows what/when but something good is coming and I will be right here fully loaded when it does...good luck to ya!!
Perfect place to pick up some more right now @ 14.90. Head fake this morning. Bet we close up on the day.
No matter...as I have said before, anytime there is a retracement for this stock it's a good time to buy...
$PROF long and strong!!
Yes Vipyr AVCO sure did explode yesterday...
and we did it with the most daily volume we have seen in the last 3 and a half months. Obviously something is going on. Will be interesting to see if we get some kind of news out soon.
Notice the daily Doji bar that was created last Wednesday on 8/5 that took out the shelf of support (and stoplosses) formed over the last several months at 1.52. On that day we saw a low of 1.50. Since that Doji (head fake) day, we have been nothing but up!
The key now is can we follow thru and close up above $2.00?? We do that and we are headed to $5.00 (fills in massive gap that was formed on 4/24/19) as a first target and then $13.50 (the all time high) and beyond!
$AVCO long and strong!
Absolutely...they are no fools and will get a good price. Hope you snag those shares and bet you land them on the morning opening...good luck!
When opportunity comes a knocking...
Steve Forte, the senior finance executive with multiple successful multi-billion-dollar M&A's under his belt, will make sure PROF gets great terms and will not dilute shares unnecessarily. This deal will definitely help the company...he and his team will make sure of that.
That being said most traders at first will not look at it this way and they will sell shares down on the open tomorrow. The most obvious spot to look for a bargain is at the 50% fib retracement of the last rally right around 15-14.95. This price area is also in confluence with the approximate top of the previous 2 month sideways channel...
Management knows what they are doing...like I said in my previous post take advantage of the dips/retracements. $15.00 is an obvious place to do just that IMHO...
Here is a link to quickly check for any new Tulsa-pro locations:
https://tulsaprocedure.com/tulsa-centres/procedure-centre-usa/
Yes...agree it is curious why they did not do a PR for the new Mayo Clinic opening but oh such good news for all of us that own this beautiful little company. This is just the very beginning of our growth.
The overall market saw quite a reversal yesterday and PROF got caught up in that. PROF is not going to go straight up...it's only normal for price to take breaks. Take advantage of the dips/retracements with confidence knowing you are buying into a company that is going to disrupt the way men all around the world treat their prostate issues...
Beautiful trend in PROF. Slow and steady. Next speed bump is the all time high at 20.6. Once we kick around that price for a bit it's nothing but blue sky up after that. Phenomenal stock for a very long term hold! I am sure we will be getting some good news out of the company one of these days...but no rush!
Remember it is a rare man/woman who can be both right and sit tight. Stick this stock in your back pocket and forget about it... IMHO.
Hello Investophile...I agree. Was expecting a breakout up above 2.0 last week and we almost had it.
There are a few dynamics in play right now...There is a gap that was created on Thursday June 25th at 1.60 that traders would love to fill but so far have been unable to. There is also a big event happening this weekend on Saturday at the eighth annual Lu Daopei Hematology forum, the largest Hematology Conference in Asia. Avalon will be presenting details of their phase 1 clinical update from the AVA-001 study which went very well. There is always a chance they may make some other big announcement from there as well... So will see what Wednesday brings if we stop the recent downward slide. This weekend’s news could be the trigger we need to get us up and over $2.0. Will know soon enough...
Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001
https://finance.yahoo.com/news/avalon-globocare-announces-successful-completion-133010567.html
GlobeNewswire•June 29, 2020
- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity or Adverse Side Effects; Successfully “Bridging” to Allogeneic Bone Marrow Transplant with Curative Intent
- Results will be Presented on July 11, 2020 at The Eighth Annual Lu Daopei Hematology Forum, the largest Hematology Conference in Asia
FREEHOLD, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, announced today it has successfully completed Phase I first-in-human clinical study of its leading Chimeric Antigen Receptor (CAR) T-cell therapy candidate, AVA-001 (National Institute of Health clinical trial registration number: NCT03952923). Nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) have achieved complete remission (CR rate of 90%) within one month after the initiation of AVA-001 CAR T-cell therapy treatment. The treatment with AVA-001 was generally well tolerated with minimal toxicities and adverse side effects. No neurotoxicity or greater than Grade-1 cytokine release syndrome was observed in this cohort of patients treated with AVA-001. All patients who achieved CR successfully proceeded to allogeneic bone marrow transplant with curative intent. AVA-001 is a third generation CAR T-cell therapy which involves the 4-1BB (or CD28) co-stimulation signaling pathway. Accessary laboratory testing that accompanied this pilot clinical study has demonstrated evidence of enhancement in CAR T cell persistence and protection against CAR T cell exhaustion.
Avalon will present the results of this AVA-001 Phase 1 clinical trial on July 11,2020 at The Eighth Annual Lu Daopei Hematology Forum, the largest Hematology Conference in Asia (which will be held online according to the organizer due to the COVID-19 pandemic).
“We are excited and pleased to achieve these successful outcomes with our AVA-001 CAR T-cell therapy. This paradigm of bridging CAR T-cell therapy to bone marrow transplant creates a new therapeutic horizon with curative potential for patients with relapsed/refractory B-ALL and other hematologic cancers,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We look forward to advancing our mission to improve cancer patient care and save lives,” said Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (AVCO) is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEXTM), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Yeah Prfmf1...hard to tell until there are a few more trades in the extended hours. It may just be some yahoo that does not know what he is doing but who knows. No news out this morning so no Monday gap. However it was telling the way the stock was down most of the day and came right back up at the end. The next obvious target for traders/investors is the all time high at 20.6.
Hello hayfarmer...couldn't agree with you more...would much rather wait for the company to really grow and prove itself and demand the 3 figure price. Steve Forte and crew are no slouches and they will demand top dollar.
Also agree that it is more likely any news that comes out might be on the CPT code being approved or as you said adoption of the technology by some medical organization. Most likely any news that comes out before the bell Monday will be very good news for us shareholders.
Also agree that you do tend to get gaps that reverse when they close near their highs but with the exception when they are coming out of a base like the one we are coming out of now. Take a look at any weekly chart of any random stock and you will find many big moves started with a Monday morning gap coming out of a base (sideways price action).
But we are not talking about any random stock here. Have a look at the weekly chart for PROF. If you look very carefully going back to August of 2019 on the weekly chart of PROF you will find 5 separate Monday morning break-away gaps in its history...some coming out of a base, some not. It's a little late now or I would screenshot the chart here and point them out. We almost had one this past Monday but the gap did get filled in just before price shot up this week.
If news does happen to come out this Monday we will certainly get a Monday morning gap and hopefully this time it does not get filled in and PROF heads much higher taking out the old all time high of 20.6. We will know soon enough...
Have a great weekend!
Thank you mst401k for breaking down the prospective earning numbers in detail...fantastic, and gives me even more confidence that we have found a unicorn here. I do not know about the MRIs but wouldn't most facilities already have them? I do not believe it has been brought up as a concern in any of the share holders meetings but certainly something to look into.
One thing you may not be aware of that also gives me extreme confidence in this company is that back in August of 2019, Profound Medical brought on board Steve Forte. Steve, is a senior finance executive with multiple successful multi-billion-dollar M&A's under his belt. He is now a director at Profound and member of the board's audit committee. There is no way a guy of this caliber would go to work for a company unless he saw huge potential. Just have a look at this link of his announcement going to Profound and I think you will agree.
https://biotuesdays.com/2019/08/15/profound-medical-names-senior-finance-executive-steve-forte-to-board/
One other point...have you ever been to inspire.com's giant message board? If not just do a search for "inspire.com, tulsa-pro". Many users there giving positive 3rd party testimonies concerning Profound's Tulsa-pro's prostate treatment. The membership at Inspire is free..
Of course anyone’s guess why PROF is breaking out at this moment in time but my suspicion is someone knows something about new news (Insurance news?) coming out and they are buying the stock up like crazy. And because the stock closed very near it’s high on a Friday afternoon my experience tells me the news will come out sometime before the market opens Monday morning creating a breakout gap at the open. Again, all just an educated guess. I will say whatever scenario plays out it look like we are going higher...much higher.
"Houston...we are clear for takeoff..."
Would be surprised if we don't get a Monday morning gap up.
This should help you:
This is an excerpt from one of TJ Robert's excellent analysis of Profound Medical written back on April 3rd of this year on Seeking Alpha about revenue and prospects for the future...I would include a link but it's from SA's paid subscription area. I hope this helps...
I would hurry with your due diligence/analysis though as PROF looks like it is about to breakout to the upside...In fact if PROF should close at or near its high today, Friday, there is a good chance we open with a gap up Monday morning IMHO.
--------
"Profound's goal is to have ~15 clinics performing the Tulsa-Pro procedure by end of 2020 with at least 20 signed agreements. Profound will have multiple RadNet sites up and running by the end of Q3-2020. In their first year of performing the Tulsa-Pro procedure, clinics are only expected to perform ~40 procedures due to the need for teaching other professionals. In the second year, however, ~100 procedures will be possible, which is a 2.5x improvement in the revenue channel for a given clinic.
The out-of-pocket market represents ~5% of the total available market size, so with just this market slice alone, Profound has the capability of generating ~$260M in revenue where each procedure now generates $6k in recurring revenue. When the company gets a temp C-code, that could dramatically expand the out-of-pocket market size as patients would only have to pay "~$2k-4k versus current $15k-$25k total cost; and then, there would be no cost after a CPT code is obtained which would expand market size to ~$5.2B".
Now, $260M in annual revenue would be astronomical growth from $8M. At ~40k patients per year, 200 working days, and 4 treatments per day, that's about 800 per year or 50 clinics working non-stop. Extrapolating the market size to $5.2B means 20x growth or 1,000 clinics working non-stop or 800,000 treatments per year throughout the world. With a TAM of over 1.2M new cases in 2018, and having the most superior prostrate treatment on the market, Profound holds great potential for investors.
From Profound's latest earnings call, management spoke of additional contract negotiations in play, with one business customer almost ready to make a Tulsa-Pro announcement and begin performing the procedure. In terms of revenue, it takes a full quarter (90-days) from the contract-signing before the first patient can be treated; Profound estimates that this timeframe can be reduced to just 75-days as more-experienced staff become available.
In summary, investors should recognize that more clinics, more daily procedures, and faster turnaround times for new business customers adopting Tulsa-Pro, will result in more revenue. Investors should consider the size of the prostate cancer and BPH markets such that once a CPT code is issued, Profound could eventually become like McDonalds with billions and billions served. Furthermore, according to Profound at their last earnings call, there is already a long line of patients awaiting the Tulsa-Pro procedure, so the need for a huge sales and marketing force increasing OpEx is minimized."
-------
Company Information
https://kitovpharma.investorroom.com/
Kitov Pharma is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare and business professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s flagship combination drug, Consensi™, achieved the primary efficacy endpoints for its Phase III and Phase III/IV clinical trials, and was approved by the U.S. FDA for patients suffering from osteoarthritis pain and hypertension. NT-219, which is developed by Kitov's majority-owned subsidiary, TyrNovo Ltd., is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives.
Here is a little more info:
https://en.globes.co.il/en/article-kitov-pharma-raises-35m-from-institutional-investors-1001333551
!!NEWS OUT!! - Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate
June 25, 2020 09:02 AM ET (BZ Newswire) -- News
- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a novel S-layer SARS-CoV-2 (COVID-19) vaccine
- Avalon and BOKU have already begun to develop a novel SARS-CoV-2 vaccine that can be administered by an intranasal or oral route
- Avalon and Professor Sleytr of BOKU have jointly filed a USPTO provisional patent application on a novel design and implementation of S-layer structure technology for vaccine development
FREEHOLD, N.J., June 25, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, announced today a strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine that can be administered by an intranasal or oral route against SARS-CoV-2, the novel coronavirus that causes COVID-19 disease.
The principal investigator of the co-development project is BOKU's Professor Uwe B. Sleytr, an eminent member of the Austrian Academy of Sciences. Professor Sleytr is a pioneer of applied surface layer ("S-layer") nanotechnology, based on the repetitive protein structures that make up the outer surface of microbial cells. Dr. Eva-Kathrin Ehmoser, Professor and Head of the Institute for Synthetic Bioarchitectures at BOKU, serves as the co-principal investigator of the COVID-19 vaccine program.
Given the continued rise of COVID-19 cases around the world, Avalon and the BOKU scientists are working closely to co-develop a novel SARS-CoV-2 vaccine that would induce a sufficient immune response to prevent a severe form of COVID-19, which causes morbidity and often mortality. This vaccine strategy has the dual advantages of ease of manufacturing and delivery. The candidate vaccine is derived from a fusion of an S-layer viral particle mimic with the SARS-CoV-2 spike protein and could be delivered non-invasively via the nasal or oral passageways, rather than a needle-based injection into the muscle or under the skin. The S-layer protein-based vaccine is expected to both decrease the severity of a SARS-CoV-2 infection—preventing the more severe respiratory inflammation and organ damage seen in many COVID-19 patients—and build immunity against the virus.
This strategic partnership with BOKU leverages Avalon's expertise and resources in bio-manufacturing infrastructure and clinical study implementation with the scientific capabilities and deep experience of the laboratories of Professors Sleytr and Ehmoser at BOKU. Professors Sleytr and Ehmoser have already made substantial progress by developing the proprietary techniques necessary to synthesize conjugate vaccines consisting of an S-layer artificial viral envelope linked to a viral antigen. As a proof of concept, the investigators have also shown that these types of protein conjugate vaccine candidates are able to elicit immune-protective antibody responses.
Avalon and Professor Sleytr have jointly filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) pertaining to the nanoparticle S-layer based vaccine against SARS-CoV-2.
The research is part of an ongoing and broader collaboration between Avalon and BOKU that will utilize S-layer technology to accelerate additional vaccine programs for other respiratory infections including different strains of the flu (influenza A/B), respiratory syncytial virus (RSV), and other viruses. As part of the partnership, Avalon is also actively exploring other practical uses of S-layer technology including targeted drug delivery, diagnostic devices, and therapeutic applications.
"We are encouraged by the progress we have made so far to develop a novel COVID-19 vaccine during this unprecedented world-wide health crisis," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "We are working swiftly and diligently with BOKU to complete the laboratory testing and characterization of the S-layer fusion protein SARS-CoV-2 vaccine candidate. We believe that our novel vaccine approach has the potential to be effective. Importantly, this vaccine candidate could be manufactured and delivered more rapidly compared to traditional vaccines, providing access and immunization to a larger population of people around the globe to help combat the COVID-19 pandemic."
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ:AVCO) is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEXTM), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information: Avalon GloboCare Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728 PR@Avalon-GloboCare.com
Investor Relations: Crescendo Communications, LLC Tel: (212) 671-1020 Ext. 304 avco@crescendo-ir.com
Copyright © 2020 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Well I think it's clear from my "all in" response that I feel the risks are low. But that being said I can just parrot what TJ Roberts said and that was to remember this is a Canadian company and Trump and Trudeau are not best of buddies and Profound is going to need the US Fed's help at CMS for help getting the final approval for insurance.
I myself am not worried about getting approval for insurance in a timely manner as this new treatment will save insurance companies money and CMS will feel the pressure no matter if a Canadian company or not.
Profound is also working on a way to get around this obstacle quicker by going to private hospitals for validation and using an already existing C-code for insurance. The idea of this is if the hospitals approve the government will soon follow. Investors are anticipating this and is why we are starting to see the recent upward price action.
For me PROF is a very long term hold and am willing to wait for however long it takes to get insurance approval. We are looking at a company here that is going to change the way the majority of us men treat their prostate issues should they come up. PROF will be the McDonald's of prostate treatments someday...worth the wait says me.
Yes, welcome mst401k!!
How much are we each holding % wise of our portfolios of PROF? Two weeks ago, this is how I responded to TJ Roberts about this very subject over at Seeking Alpha. TJ is the guy who wrote an excellent analysis of PROF for SA and I was making a comment about how I felt about PROF..
-------------------------------------------------------
"...sell the house, the ranch, the farm and the Mercedes and back the truck up and buy PROF right now. Where are you going to find a company this relatively unknown that has such a disruptive superior treatment for a serious ailment that is so prevalent in half the population? Excellent upper management/sales force. Excellent share structure. Already FDA approved. No debt. Possible buyout candidate. Raving accolades from patients on 3rd party message boards. The treatment just now emerging into the US....
We may see a breakthrough in insurance in 3 days or 3 years but by then you certainly are NOT going to be able to pick up PROF for under $20.00.
My suspicion is we are going to see a breakout of upward price momentum soon. Since May 1st we have seen price backing and filling coiling tighter and tighter more or less around the $12.50 area. On balance volume is currently stair stepping up nicely.
Pushing my sizable stack of chips across the table and all in..."
----------------------------------------------------
Since I wrote this 2 weeks ago I have added even more to my position. Best of luck on whatever you yourself decide to do...
Thank you hayfarmer for this share...yes, somehow this article went underneath my radar.
Love this part:
"Last year at this time, Profound gave one-year follow-up data on the TULSA PRO at the annual meeting of the American Urological Association, while this year it had two-year data to present, which, in Sarugaser’s words, “was even stronger than its one-year data, further affirming TULSA’s strong efficacy and industry-leading safety profile, important accelerators of physician and patient adoption alike.”
What a little gem this stock is...In the near future though, unless it is bought out first, this company and technology will emerge into a giant...the McDonald 's of prostate treatment! Blessed to have found PROF at this still early stage.
Prfmf1...I’ve been traveling all day and was not watching the market close...Not surprised big buy orders were coming through on PROF for most of the day. The bottom line is this company has a patent and product for the very best way for men all over the world to treat their prostate issues backed by a stellar management team. Has gone through the extensive trials required and already FDA approved. Just waiting on insurance approval which could happen any day/second now. This stock is going to the moon over the next 3 - 5 years unless of course they are bought out first by a giant pharma for huge money in which case it would go to the moon overnight. Profound Medical (Tulsa-Pro) may quite possibly turn into the McDonald’s of Prostate treatments.. And you and I and other lucky people that have discovered this company at this early stage are going to become very wealthy if we play our cards right... ie just hold onto our shares and forget about them. All IMHO...everyone do your own due diligence...
Volume often dissipates during sideways coiling market action before price breaks out for a big move up...look at any stock chart!
A few fairly recent examples for PROF:
Oct 3rd - Oct 22nd 2019
Nov 18th - Dec 5th 2019
March 26th - April 3rd 2020
But look at any stock...usually the longer the sideways action and the tighter the price action the bigger the next move up as long as you have solid fundamentals to go along with the stock. PROF fundamentals are rock solid.
I am feeling very good about PROF right now! Tight coiling action on light volume...what a platform to blast off from!!
Tulsa-Pro vs HIFU
From Seeking Alpha:
TULSA-Pro (Transurethral Ultrasound Ablation) is a radically different technology than HIFU and is much gentler. TULSA-Pro is neither high-intensity nor focused and heats tissue to 55°C with a 1.3mm accuracy, whereas HIFU heats to 100°C very small sections of tissue to the point where they boil or burst, and the accuracy is only 5.0mm which results in more collateral tissue death; the after-effects of TULSA-Pro result in absorption and shrinkage over time of the prostate, whereas HIFU results in scarring or fibrosis. In addition, TULSA-Pro having continuous cool water flowing through the disposables, protecting both the urethra and rectum, is not available in other HIFU procedures. As a result, in clinical trials, TULSA-Pro had less than 3% moderate-to-severe urethral stricture versus 35% with HIFU, no GI toxicity versus 7% with HIFU, and half to a third the amount of ED as HIFU.
From Profound's website:
https://profoundmedical.com/what-is-the-difference-between-tulsa-pro-and-hifu/
Dr Fabio.com:
https://www.drfabio.com/healthblog/tulsa-pro-mri-guided-hifu-prostate-cancer-treatment-shows-promise
Much discussion about it on inspire.com but here is a little excerpt:
"I did have Tulsa Pro as salvage treatment after failed radiation. I wish it had been available back then but unfortunately that was not the case.
I feel that Tulsa has many advantages over other treatments due to real time imaging and also because it has cooling capabilities that prevent damage to nearby tissue. Also, unlike traditional HIFU, it can treat anywhere in the gland.
I found the treatment to be easy. Side effects were wearing a catheter for about 5 days with some urgency for a few weeks (since disappeared). I had ED prior to the Tulsa as a result of the radiation, that remains unchanged and is managable with meds.
I spent one night in hospital."
We are just waiting on the insurance temporary C-code (could be announced at anytime now) which will cover the $4k-$6k TULSA-PRO cost but still not the physician fees.
The daily AVCO charts looks like they are going to have to spike price down first through 1.50 where there is a flat line of support and take out all the stop losses that are surely sitting there before they bring price back up.
This is a solid emerging biotech company with a lot of potential...first need to take some heat before it starts on its journey north. Hold tight IMHO!
MORE NEWS OUT TODAY!
Avalon GloboCare Announces Three-Way Material Transfer Agreement with Weill Cornell Medicine and Arbele Limited for Development of Next Generation Cellular Immunotherapy FLASH-CAR™ Technology
Thu June 11, 2020 9:00 AM|GlobeNewswire|About: AVCO
FREEHOLD, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has entered into a three-way material transfer agreement (MTA) with Weill Cornell Medicine in New York City and the Company’s strategic partner, Arbele Limited.
With this agreement, Avalon GloboCare Corp. and Arbele Limited intend to collaborate with Weill Cornell Medicine and co-develop the standardized laboratory steps necessary to generate clinical-grade CAR-T and CAR-NK cells for use in future human clinical trials with Avalon’s first FLASH-CAR™ platform candidate, AVA-011. This step, called process development, will provide the bridge between Avalon’s benchtop research and the bio-manufacturing processes to potentially deliver the clinical-grade cellular immunotherapy product to patients.
“We are excited about this agreement to translate our cellular therapy candidates into standardized, clinical-grade cell products that could be used in future clinical trials. This step reflects our dedication to establishing an infrastructure to develop our cellular immunotherapy candidates and to maintain the highest possible standards for generating clinical-grade cells for human cancer trials,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.
AVA-011 is a next generation cellular immunotherapy candidate using Avalon’s FLASH-CAR™ that targets both CD19 and CD22 tumor antigens on cancer cells. Avalon has already successfully completed pre-clinical research on AVA-011, including tumor cytotoxicity studies. (See May 8, 2020 press release, ‘Avalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR™ Technology for Blood Cancers’)
Avalon’s next generation immune cell therapy using FLASH-CAR™ technology is being co-developed with the Company’s strategic partner Arbele Limited. The adaptable FLASH-CAR™ platform may be used to create personalized cancer cell therapy from a patient’s own cells, as well as off-the-shelf cell therapy from a universal donor, expanding the reach of cancer patients that could be treated.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy and exosome technology. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEXTM), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com
Source: Avalon GloboCare Corp. 2020 GlobeNewswire, Inc.
I spent some time today looking at "inspire.com tulsa-pro". Very good 3rd party message board info there and feedback of the Tulsa-Pro treatment. Makes me even more confident in what we have here. Once we get word about the insurance this train will be heading north in a hurry...
Here are a couple of fairly recent articles on Profound Medical:
This one came out right before Covid 19 hit:
https://www.cantechletter.com/2020/01/profound-medical-gets-2020-best-pick-honours-from-raymond-james/
Here is another one:
https://www.urologytimes.com/view/prostate-ablation-technique-yields-positive-results-1-year
Oh...by the way...one of those "buyers" today was me...couldn't let you have all the fun Prfmf1 ...lol !!
Exactly...it's getting caught up with the rest of the market and gapped down on low volume today. They have almost already filled the morning gap.
Even if we do take more heat going down, knowing what we own here gives me great confidence. They can not keep this stock/company down much longer. We have found a company that is going to change the way most men deal with their prostate issues and yet at this moment in time only a relatively few people know about it. A treatment this effective and already FDA approved will not be in the dark for long. HUGE opportunity here IMHO...
More backing and filling today on lighter volume...the longer it continues to back and fill the bigger the trend up when it does breakout!
Hmm...For some reason TD Ameritrade shows a notice that earnings are coming out today for AVCO but looks like they are not due out till August...